Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19

Lancet Microbe. 2021 Sep;2(9):e424. doi: 10.1016/S2666-5247(21)00189-0. Epub 2021 Jul 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Neutralizing
  • COVID-19 Drug Treatment*
  • Humans
  • Immunocompromised Host
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • bamlanivimab